The Phase 2a trial of batoclimab showed a 76% response rate and a 56% ATD-free response rate in patients uncontrolled on antithyroid drugs after 12 weeks. How do these findings compare to existing treatment options for Graves' Disease, and what does this mean for patients who have exhausted other therapies?

The trial results revealed a strong correlation between IgG reduction and clinical response, with a 77% reduction in IgG leading to higher response rates. Can you explain the significance of IgG lowering in treating Graves' Disease, and how might this influence the design of future therapies?

While the high-dose batoclimab (680 mg) achieved stronger outcomes, reducing the dose to 340 mg resulted in lower response rates. How important is dose optimization in achieving sustained clinical benefits, and what considerations should be taken when transitioning patients to maintenance therapy?

Roivant has announced plans to initiate a pivotal trial for IMVT-1402 by year-end. Based on the data from batoclimab, what are the key factors that should be incorporated into the pivotal trial to maximize its chances for success and regulatory approval?

Real-world data indicates that 25-30% of patients with Graves' Disease are uncontrolled on antithyroid drugs, representing a significant unmet need. How does IMVT-1402 address this gap, and what are the potential advantages it may offer over current treatment options?

Given that autoimmune treatments often come with a range of side effects, how did batoclimab perform in terms of safety and tolerability in the Phase 2a trial? What are the potential long-term safety considerations for IMVT-1402 as it moves toward pivotal trials?

With a sizable portion of Graves' Disease patients remaining uncontrolled on current therapies, what do you think are the commercial prospects for IMVT-1402? How might its potential 'best-in-class' profile impact its adoption and use in clinical practice?

Roivant has aligned with the FDA on the pivotal trial design for IMVT-1402. How significant is this alignment in expediting the development process, and what are the key regulatory considerations that will be important as the program advances?